Loading stock data…
DNTH
$84.57+3.35 (+4.12%)
After Hours$84.57+0.00 (+0.00%)· Last close Jun 9
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dianthus Therapeutics, Inc. in the Healthcare sector is trading at $84.57 with a market capitalization of $4.6B. Wall Street consensus targets $125.83 (12 analysts), implying a +48.8% move over the next 12 months. The stock is currently near its 52-week high of $96.50, remaining 52.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$84.57
Potential Downside
0%
Whystock Fair Value$84.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$125.83+48.8%
Range$98.00 – $200.00
Fundamentals
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.46%
Volume
Today's trading volume
619,513
Recent News
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125. The firm also reiterated its Strong Buy rating on the stock, which currently yields a revised upside potential of […]
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier
Dianthus Therapeutics Inc (NASDAQ:DNTH) is among the best 52-week high US stocks to buy. On March 26, William Blair reaffirmed an Outperform rating on Dianthus Therapeutics Inc (NASDAQ:DNTH) stock. This action followed an FDA update on safety requirements for Dianthus Therapeutics’ claseprubart clinical trials. In the safety update, the FDA has dropped antinuclear antibodies as […]
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise
Dianthus Therapeutics (DNTH) is in focus after updating investors on LBL-047, its lead autoimmune asset, including new priority indications, partnership terms with Leads Biolabs, and funding raised to support clinical development. See our latest analysis for Dianthus Therapeutics. The recent update on LBL-047 and the earlier financing round come after a very strong run. The latest share price is $86.16, with a 90 day share price return of 75.09% and a 1 year total shareholder return of about...
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.